Tunes isn't the most accurate or most powerful CD ripper, but it's the best for most people with demanding digitizing needs.

The third day of the J.P. Morgan Healthcare Conference has begun, marking the last full slate of conference sessions and ...

A lawsuit against Pump.fun and Solana executives has been refiled. It claims that executives orchestrated a wide-ranging pump ...

Abstract: Organisations are flooded with enormous amounts of data from many sources in the big data era. Effective query processing strategies are crucial for deriving significant insights and guiding ...

Abstract: Semi-Supervised Partial Label Learning (SSPLL) is an important branch of weakly supervised learning, where the data consists of both partial label examples and unlabeled ones. In SSPLL, the ...

The latest proposal is designed to deter future Russian aggression. But Russia is not part of the talks and has shown little willingness to negotiate. By Michael D. Shear Steven Erlanger and ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

This paper presents a theoretical framework for parallelizing the FD3 algorithm, which estimates the capacity, information, and correlation dimensions of chaotic time series using the box-counting ...

WASHINGTON, Dec 10 - President Donald Trump's administration officially launched his "Trump Gold Card" visa program on Wednesday to provide a pathway, with a steep price, for non-U.S. citizens to get ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...